Published on
May 18, 2018
- 13:25 GMT
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes 11 subjects enrolled through > 4,200 days cumulative …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...
